CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 54 enrolled
Drug / intervention
Dupilumab (SAR231893)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04823130
NCT04823130Phase 4Completed
CompareCT.gov

A Multi-center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Sanofi·interventional·Posted Mar 30, 2021·Updated Sep 16, 2025

In Brief

A Phase 4 clinical trial evaluating Dupilumab (SAR231893) for Dermatitis Atopic. Completed, enrolled 54 participants across 3 sites in 2 countries.

Detailed Summary

Primary Objective: \- Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus. Secondary Objectives: * Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus. * To evaluate the efficacy of dupilumab in AD participants with chronic pruritus. * To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis Atopic
CountriesGermany, United States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedMar 30, 2021
Enrollment StartApr 22, 2021
Primary CompletionJun 30, 2022
Study CompletionAug 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.3 years ago

Interventions

Dupilumab (SAR231893)drug

Pharmaceutical form: solution for injection Route of administration: subcutaneous